Revenue: As of FY2026 Q2, the actual value is USD 11.41 M, beating the estimate of USD 10.27 M.

EPS: As of FY2026 Q2, the actual value is USD -0.16, missing the estimate of USD -0.155.

EBIT: As of FY2026 Q2, the actual value is USD -8.15 M.

TriSalus Life Sciences, Inc. announced its financial results for the second quarter ended June 30, 2026, via a press release issued on August 6, 2026, which was attached as Exhibit 99.1 to the Current Report on Form 8-K. However, the provided reference text does not contain any specific financial or operational metrics, including segment revenue, net income, gross margin, operating profit, operating margin, operating costs, cash flow (operating or free), or unique company-specific financial indicators. Similarly, no forward-looking statements or guidance content is available in the provided reference text.